# OnCo record nct03755791 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct03755791/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct03755791", "NCT03755791" ;
  schema:name "Study of Cabozantinib in Combination With Atezolizumab Versus Sorafenib in Participants With Advanced Hepatocellular Carcinoma (HCC) Who Have Not Rece"@en ;
  schema:alternateName "COSMIC-312"@en ;
  schema:description "A phase 3 trial of Cabozantinib, Sorafenib, Atezolizumab in hepatocellular carcinoma, run by Exelixis, active and no longer recruiting."@en ;
  schema:url <https://onco.cc/trials/nct03755791/> ;
  schema:dateModified "2026-09-22"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT03755791> ;
  onco:status "active" ;
  onco:tag "ctgov-ingest" ;
  onco:phase "3" ;
  schema:startDate "2018-06-10" ;
  onco:cancers <https://onco.cc/cancers/hcc/>, <https://onco.cc/cancers/hcc-advanced/> ;
  onco:technologies <https://onco.cc/technologies/antiangiogenic/>, <https://onco.cc/technologies/checkpoint-inhibitor/>, <https://onco.cc/technologies/kinase-inhibitors/> ;
  onco:drugs <https://onco.cc/drugs/cabozantinib/>, <https://onco.cc/drugs/sorafenib/>, <https://onco.cc/drugs/atezolizumab/> ;
  onco:companies <https://onco.cc/companies/exelixis/> .